title: Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
abstract: Gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT or platelet-derived growth factor receptor A (PDGFRA), and treatment with the tyrosine kinase inhibitor imatinib yields responses in the majority of patients. However, most patients develop secondary resistance, which is associated with a dismal prognosis. Histone deacetylase inhibitors (HDACI) have been shown to enhance imatinib activity in imatinib-resistant chronic myelogenous leukemia. Against this background, we explored whether HDACI might provide an alternative therapeutic strategy to KIT/PDGFRA kinase inhibitors in GIST. Inhibition of cell proliferation by HDACI was seen in KIT-positive but not in KIT-negative GIST cell lines, suggesting that HDACI activity is mainly conferred by targeting oncogenic KIT. KIT activity, expression, and activation of downstream pathways were strongly inhibited by several HDACI (SAHA, LBH589, VPA, trichostatin A, and NaButyrate). SAHA and LBH589 induced apoptosis in KIT-positive GIST, and strong synergism with imatinib was observed at low concentrations of SAHA and LBH589. Mechanistically, treatment with HDACI reduced KIT mRNA transcript levels and led to strong acetylation of HSP90, interfering with its activity as KIT chaperone. These results provide preclinical evidence for a disease-specific effect of HDACI in KIT-positive GIST, which could translate into therapeutic activity.
authors.affiliation: Sarcoma Center, West German Cancer Center, University of Essen, Medical School, Essen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Mühlenberg
authors.forename: Yixiang
authors.initials: Y
authors.lastname: Zhang
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Wagner
authors.forename: Florian
authors.initials: F
authors.lastname: Grabellus
authors.forename: James
authors.initials: J
authors.lastname: Bradner
authors.forename: Georg
authors.initials: G
authors.lastname: Taeger
authors.forename: Hauke
authors.initials: H
authors.lastname: Lang
authors.forename: Takahiro
authors.initials: T
authors.lastname: Taguchi
authors.forename: Martin
authors.initials: M
authors.lastname: Schuler
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Fletcher
authors.forename: Sebastian
authors.initials: S
authors.lastname: Bauer
mesh_terms: D000107:Acetylation; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D000077337:Vorinostat
chemical_list: D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat; D019009:Proto-Oncogene Proteins c-kit; D006655:Histone Deacetylases
references.citation: Cancer Res. 2003 May 1;63(9):2118-26
references.pmid: 12727828
references.citation: Oncogene. 2001 Aug 16;20(36):5054-8
references.pmid: 11526490
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4342-9
references.pmid: 14645423
references.citation: Nat Rev Cancer. 2001 Dec;1(3):194-202
references.pmid: 11902574
references.citation: Stem Cells. 2004;22(6):1070-84
references.pmid: 15536197
references.citation: Oncogene. 2007 Aug 13;26(37):5420-32
references.pmid: 17694083
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4764-74
references.pmid: 16954519
references.citation: Cancer Sci. 2005 Feb;96(2):116-9
references.pmid: 15723656
references.citation: Oncogene. 2007 Nov 29;26(54):7560-8
references.pmid: 17546049
references.citation: J Biol Chem. 1998 Dec 4;273(49):32608-13
references.pmid: 9829999
references.citation: Clin Cancer Res. 2006 Apr 15;12(8):2622-7
references.pmid: 16638875
references.citation: J Invest Dermatol. 2005 Nov;125(5):1045-52
references.pmid: 16297208
references.citation: Mol Cancer Ther. 2006 Sep;5(9):2203-10
references.pmid: 16985053
references.citation: Nat Rev Drug Discov. 2002 Apr;1(4):287-99
references.pmid: 12120280
references.citation: Lancet Oncol. 2005 Apr;6(4):249-51
references.pmid: 15811621
references.citation: Anticancer Res. 2006 Mar-Apr;26(2A):1247-52
references.pmid: 16619531
references.citation: Nat Rev Drug Discov. 2007 Jan;6(1):21-2
references.pmid: 17269160
references.citation: Leukemia. 2005 Sep;19(9):1579-89
references.pmid: 16015388
references.citation: Science. 1998 Jan 23;279(5350):577-80
references.pmid: 9438854
references.citation: J Biol Chem. 2005 Jul 22;280(29):26729-34
references.pmid: 15937340
references.citation: Oncogene. 2008 Sep 18;27(42):5624-34
references.pmid: 18521081
references.citation: Oncogene. 2004 May 13;23(22):3999-4006
references.pmid: 15007386
references.citation: Cancer Cell. 2005 Feb;7(2):129-41
references.pmid: 15710326
references.citation: Mol Cell. 2005 May 27;18(5):601-7
references.pmid: 15916966
references.citation: Cancer Res. 2001 Nov 15;61(22):8118-21
references.pmid: 11719439
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1743-9
references.pmid: 16551858
references.citation: Science. 2003 Jan 31;299(5607):708-10
references.pmid: 12522257
references.citation: Mol Cell. 2007 Jan 12;25(1):151-9
references.pmid: 17218278
references.citation: J Pathol. 2001 Apr;193(4):505-10
references.pmid: 11276010
references.citation: Pharmacology. 2006;77(1):11-6
references.pmid: 16534250
references.citation: J Clin Oncol. 2008 Feb 1;26(4):620-5
references.pmid: 18235121
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
references.pmid: 10954755
references.citation: Cancer Res. 2003 Aug 15;63(16):5126-35
references.pmid: 12941844
references.citation: Adv Cancer Res. 2004;91:137-68
references.pmid: 15327890
references.citation: J Biol Chem. 2005 Oct 7;280(40):33792-9
references.pmid: 16087666
references.citation: Blood. 2003 Apr 15;101(8):3236-9
references.pmid: 12446442
references.citation: J Biomol Screen. 2002 Jun;7(3):223-31
references.pmid: 12097185
references.citation: Ann Surg. 2000 Jan;231(1):51-8
references.pmid: 10636102
references.citation: J Immunol Methods. 1993 Mar 15;160(1):81-8
references.pmid: 7680699
references.citation: Cancer Res. 2006 Sep 15;66(18):9153-61
references.pmid: 16982758
references.citation: Nature. 2007 May 24;447(7143):407-12
references.pmid: 17522673
references.citation: APMIS. 2005 Apr;113(4):264-8
references.pmid: 15865607